Quva and CAPS collaborate to maintain supply of

Quva 与 CAPS 合作维持供应

critical medications to U.S. hospitals.

向美国医院提供关键药物。

SUGAR LAND, Texas and ALLENTOWN, Pa.

德克萨斯州舒格兰和宾夕法尼亚州阿伦敦

,

，

Sept. 8, 2026

2026年9月8日

/PRNewswire/ --

/美通社/ --

QuVa Pharma, Inc. ('Quva') and Central Admixture Pharmacy Services, Inc. ('CAPS') today announced that Quva has acquired a range of essential medications from CAPS following CAPS' decision to exit the 503B sterile compounding business. Quva expects to begin introducing selected products from the acquired portfolio in phases later in 2026 and to expand its offerings over the following six (6) months..

QuVa Pharma, Inc.（“Quva”）与 Central Admixture Pharmacy Services, Inc.（“CAPS”）今日宣布，在 CAPS 决定退出 503B 无菌配药业务后，Quva 已从 CAPS 收购一系列基本药物。Quva 预计将于 2026 年晚些时候开始分阶段推出所收购产品组合中的选定产品，并在随后的六（6）个月内逐步扩展其产品供应。

'We are proud to work with Quva, a recognized leader in 503B outsourcing manufacturing, to help ensure continued access to a number of essential medications,' said Michael Parden, Chief Executive Officer of B. Braun of America. 'Products such as Cardioplegia, Total Parenteral Nutrition and Heparin play an important role in patient care, and this transition supports continuity of supply for the patients and providers who depend on them.

“我们很自豪能与503B外包制造领域的公认领导者Quva合作，以帮助确保持续获得多种基本药物，”美国贝朗医疗首席执行官Michael Parden表示。“心脏停搏液、全肠外营养和肝素等产品在患者护理中发挥着重要作用，此次过渡有助于为依赖这些产品的患者和医疗机构保障供应的连续性。”

We also appreciate Quva's commitment to providing employment opportunities for CAPS colleagues currently supporting our local 503B sterile compounding operations.'.

我们还赞赏 Quva 致力于为目前支持我们本地 503B 无菌配药运营的 CAPS 同事提供就业机会。

Operating from more than 200,000 sq. ft. of FDA-registered 503B manufacturing facilities in New Jersey and Texas and 100,000 sq. ft. of forward distribution centers in Texas and Arizona, Quva serves more than 3,500 hospitals and health system customers nationwide with its broad portfolio of sterile compounded medications manufactured under rigorous quality standards..

Quva 依托其位于新泽西州和德克萨斯州的超过 20 万平方英尺的 FDA 注册 503B 生产设施，以及位于德克萨斯州和亚利桑那州的 10 万平方英尺的前置配送中心，向全美 3,500 多家医院和医疗系统客户提供严格按照质量标准生产的无菌复合药物产品组合。

'We appreciate the opportunity to partner with CAPS to maintain the supply of these critical medications,' said Stuart Hinchen, Chief Executive Officer of Quva. 'Health systems depend on prepared medications that are essential to patient care but difficult to produce reliably at scale. This acquisition reflects our commitment to investing in the specialized products, manufacturing capabilities, quality systems, distribution infrastructure, technology, and people needed to support these critical medication categories.

Quva 首席执行官 Stuart Hinchen 表示：“我们珍视与 CAPS 合作以维持这些关键药物供应的机会。医疗系统依赖于那些对患者护理至关重要但难以大规模稳定生产的预制药剂。此次收购体现了我们致力于投资于支持这些关键药物类别所需的专业产品、制造能力、质量体系、分销基础设施、技术以及人才。”

We look forward to working with CAPS and our health-system customers to maintain supply and build more dependable solutions for the future.'.

我们期待与CAPS及我们的医疗系统客户合作，以维持供应并为未来构建更可靠的解决方案。

About Quva

关于 Quva

Quva helps health systems address critical medication needs across the enterprise. Through two distinct businesses, Quva supports both the supply of essential prepared medications and the use of complex medication data to improve enterprise decision-making.

Quva 帮助医疗系统解决整个企业范围内的关键药物需求。通过两个独立的业务部门，Quva 既支持基本预制药物的供应，又利用复杂的药物数据来改善企业决策。

Quva Pharma partners with hospitals and health systems to support categories of ready-to-administer and compounded medications that are essential to patient care and difficult to prepare reliably at scale.

Quva Pharma 与医院及医疗系统合作，支持对患者护理至关重要且难以大规模可靠配制的即给药剂型和复方药物类别。

Quva BrightStream connects and normalizes medication data from more than 400 source systems across sites of care, helping health-system leaders identify what matters, understand why, and make better decisions.

Quva BrightStream 连接并标准化来自400多个护理场所源系统的药物数据，帮助医疗系统领导者识别关键信息、理解其原因，并做出更优决策。

Together, Quva's businesses share a commitment to helping health systems deliver safe, dependable, and effective medication care.

Quva旗下的各业务部门共同致力于帮助医疗系统提供安全、可靠且有效的药物护理服务。

For more information, visit onequva.com.

更多信息，请访问 onequva.com。

About B. Braun

关于贝朗

B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future.

贝朗医疗公司（B. Braun）是智能输液疗法、安全有效的药房产品、患者与医护人员安全以及可持续健康解决方案领域的领导者。我们的宗旨是帮助医护人员持续提升患者满意度和治疗结果。通过打造旨在帮助医疗专业人员专注于最重要事项——即患者的产品与服务，我们具备独特的优势，能够助力医疗卫生系统在当前及未来取得成功。

B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap.

贝朗医疗总部位于宾夕法尼亚州伯利恒，是贝朗集团美国公司的一部分，旗下包括贝朗介入系统公司和蛇牌。

®

注册商标符号

and CAPS

和 CAPS

®

®

. The company employs 8,500 people at over 30 locations across North America.

该公司在北美30多个地点雇佣了8,500名员工。

Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise

在全球范围内，贝朗集团公司在64个国家拥有超过64,000名员工。以“分享专业知识”为指引

®

®

philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our

秉承这一理念，贝朗医疗持续与客户、合作伙伴及临床医生交流知识，以应对提升护理质量和降低成本的关键问题。欲了解更多关于贝朗医疗的信息，请浏览我们的

website

网站

.

。

SOURCE QuVa Pharma, Inc.

来源：QuVa Pharma, Inc.

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示